{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Infections%2C+Respiratory+Syncytial+Virus&page=9",
    "query": {
      "condition": "Infections, Respiratory Syncytial Virus",
      "page": 9
    },
    "page_size": 10
  },
  "pagination": {
    "page": 9,
    "page_size": 10,
    "total_count": 201,
    "total_pages": 21,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Infections%2C+Respiratory+Syncytial+Virus&page=10&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Infections%2C+Respiratory+Syncytial+Virus&page=8&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-15T07:21:15.090Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00016081",
      "title": "Ribavirin Compared With Standard Care in Treating Patients With Respiratory Syncytial Virus Following Stem Cell Transplantation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Infection"
      ],
      "interventions": [
        {
          "name": "ribavirin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": null,
      "start_date": "1998-03",
      "completion_date": "2003-03",
      "has_results": false,
      "last_update_posted_date": "2010-03-30",
      "last_synced_at": "2026-10-15T07:21:15.090Z",
      "location_count": 4,
      "location_summary": "Birmingham, Alabama • Chicago, Illinois • St Louis, Missouri + 1 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00016081"
    },
    {
      "nct_id": "NCT02873286",
      "title": "RSV-MVA-BN Vaccine Phase II Trial in ≥ 55 Year Old Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Respiratory Syncytial Virus Infections"
      ],
      "interventions": [
        {
          "name": "MVA-BN-RSV",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Bavarian Nordic",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "55 Years and older"
      },
      "enrollment_count": 420,
      "start_date": "2016-09",
      "completion_date": "2018-12",
      "has_results": true,
      "last_update_posted_date": "2020-09-22",
      "last_synced_at": "2026-10-15T07:21:15.090Z",
      "location_count": 12,
      "location_summary": "Redding, California • San Diego, California • The Villages, Florida + 9 more",
      "locations": [
        {
          "city": "Redding",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "The Villages",
          "state": "Florida"
        },
        {
          "city": "Savannah",
          "state": "Georgia"
        },
        {
          "city": "Stockbridge",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02873286"
    },
    {
      "nct_id": "NCT01489306",
      "title": "A Trial to Assess the Safety, Tolerability and Pharmacokinetics of MDT-637 in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Drug Safety"
      ],
      "interventions": [
        {
          "name": "MDT-637",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "MicroDose Therapeutx, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 36,
      "start_date": "2011-12",
      "completion_date": "2012-02",
      "has_results": false,
      "last_update_posted_date": "2012-04-12",
      "last_synced_at": "2026-10-15T07:21:15.090Z",
      "location_count": 1,
      "location_summary": "Cypress, California",
      "locations": [
        {
          "city": "Cypress",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01489306"
    },
    {
      "nct_id": "NCT00632463",
      "title": "RI-001 in Immunosuppressed Respiratory Syncytial Virus (RSV) Infected Patients at Risk of Lower Tract RSV Illness",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Upper Respiratory Tract Infection",
        "Lower Respiratory Tract Infection"
      ],
      "interventions": [
        {
          "name": "RI-001",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "ADMA Biologics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "2 Years to 65 Years"
      },
      "enrollment_count": 21,
      "start_date": "2008-02",
      "completion_date": "2010-05",
      "has_results": true,
      "last_update_posted_date": "2013-04-24",
      "last_synced_at": "2026-10-15T07:21:15.090Z",
      "location_count": 15,
      "location_summary": "San Francisco, California • Aurora, Colorado • Washington D.C., District of Columbia + 11 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00632463"
    },
    {
      "nct_id": "NCT04938830",
      "title": "Clesrovimab (MK-1654) in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease (MK-1654-007)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "RSV Infection"
      ],
      "interventions": [
        {
          "name": "Clesrovimab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Palivizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "1 Year",
        "sex": "ALL",
        "summary": "Up to 1 Year"
      },
      "enrollment_count": 1003,
      "start_date": "2021-11-30",
      "completion_date": "2025-08-01",
      "has_results": true,
      "last_update_posted_date": "2026-05-08",
      "last_synced_at": "2026-10-15T07:21:15.090Z",
      "location_count": 29,
      "location_summary": "Long Beach, California • Orange, California • Aurora, Colorado + 22 more",
      "locations": [
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04938830"
    },
    {
      "nct_id": "NCT03102034",
      "title": "Evaluating the Infectivity, Safety, and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (D46/NS2/N/ΔM2-2-HindIII) in RSV-Seronegative Infants 6 to 24 Months of Age",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Respiratory Syncytial Virus Infections"
      ],
      "interventions": [
        {
          "name": "D46/NS2/N/ΔM2-2-HindIII",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "24 Months",
        "sex": "ALL",
        "summary": "6 Months to 24 Months"
      },
      "enrollment_count": 32,
      "start_date": "2017-04-06",
      "completion_date": "2018-05-25",
      "has_results": true,
      "last_update_posted_date": "2022-02-08",
      "last_synced_at": "2026-10-15T07:21:15.090Z",
      "location_count": 10,
      "location_summary": "Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03102034"
    },
    {
      "nct_id": "NCT04498741",
      "title": "Drug-Drug Interaction Study Between EDP-938, Tacrolimus, Dabigatran, Rosuvastatin and Midazolam in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "RSV Infection"
      ],
      "interventions": [
        {
          "name": "EDP-938",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Dabigatran",
          "type": "DRUG"
        },
        {
          "name": "Rosuvastatin",
          "type": "DRUG"
        },
        {
          "name": "Midazolam",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Enanta Pharmaceuticals, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 89,
      "start_date": "2020-07-08",
      "completion_date": "2021-06-01",
      "has_results": false,
      "last_update_posted_date": "2021-10-13",
      "last_synced_at": "2026-10-15T07:21:15.090Z",
      "location_count": 1,
      "location_summary": "Lenexa, Kansas",
      "locations": [
        {
          "city": "Lenexa",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04498741"
    },
    {
      "nct_id": "NCT00129766",
      "title": "Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Respiratory Syncytial Virus Infections"
      ],
      "interventions": [
        {
          "name": "motavizumab (MEDI-524)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "palivizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "MedImmune LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "24 Months",
        "sex": "ALL",
        "summary": "Up to 24 Months"
      },
      "enrollment_count": 6635,
      "start_date": "2004-11",
      "completion_date": "2006-05",
      "has_results": true,
      "last_update_posted_date": "2013-08-28",
      "last_synced_at": "2026-10-15T07:21:15.090Z",
      "location_count": 120,
      "location_summary": "Birmingham, Alabama • Pike Road, Alabama • Phoenix, Arizona + 98 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Pike Road",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Benton",
          "state": "Arkansas"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00129766"
    },
    {
      "nct_id": "NCT00246480",
      "title": "RSV Disease in the Elderly",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Respiratory Infections, Acute",
        "Respiratory Syncytial Virus"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "21 Years to 99 Years"
      },
      "enrollment_count": 1401,
      "start_date": "2005-10-03",
      "completion_date": "2008-05-28",
      "has_results": false,
      "last_update_posted_date": "2019-02-04",
      "last_synced_at": "2026-10-15T07:21:15.090Z",
      "location_count": 1,
      "location_summary": "Rochester, New York",
      "locations": [
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00246480"
    },
    {
      "nct_id": "NCT04767373",
      "title": "Efficacy and Safety of Clesrovimab (MK-1654) in Infants (MK-1654-004)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Respiratory Syncytial Virus Infection"
      ],
      "interventions": [
        {
          "name": "Clesrovimab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "1 Year",
        "sex": "ALL",
        "summary": "Up to 1 Year"
      },
      "enrollment_count": 3632,
      "start_date": "2021-04-07",
      "completion_date": "2024-07-09",
      "has_results": true,
      "last_update_posted_date": "2026-02-11",
      "last_synced_at": "2026-10-15T07:21:15.090Z",
      "location_count": 51,
      "location_summary": "Dothan, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 45 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Madera",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04767373"
    }
  ]
}